Vanda Pharmaceuticals’ shares were down more than 10% at $4.45 pre-market today, as the company provided an unfavorable ...

Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as ...

Roche today released positive top-line results of the Phase III CENTERSTONE study of Xofluza (baloxavir marboxil), an ...

US CDMO BioCentriq has appointed Syed Husain as its new CEO. Husain, who brings over 20 years of experience in CDMO ...

UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...

Applied Therapeutics’ stock surged after the FDA canceled a planned Advisory Committee meeting for govorestat, a treatment ...

Upstream Bio has filed for an IPO on Nasdaq under the symbol "UPB," following recent biotech listings. The company focuses on ...

Denmark-based Bavarian Nordic and Gavi, the Vaccine Alliance yesterday announced an advance purchase agreement (APA) to ...

The atopic dermatitis (AD) market is projected to reach $16.7 billion by 2030, according to GlobalData. New therapies like ...

US companies Incyte and Syndax Pharmaceuticals today announced results from the pivotal Phase II AGAVE-201 trial of Niktimvo (axatilimab-csfr), an anti-CSF-1R antibody, in adult and pediatric patients ...

TG Therapeutics yesterday shared new five-year data from the ULTIMATE I & II Phase III trials evaluating Briumvi (ublituximab ...

Daiichi Sankyo’s (TYO: 4568) today revealed that its Vanflyta (quizartinib) has been recommended by the National Institute ...